FINWIRES · TerminalLIVE
FINWIRES

ICICI Bank Reports Higher Profits in Fiscal Q4

-- ICICI Bank's (NSE:ICICIBANK, BOM:532174) fiscal fourth quarter profits after tax grew by 8.5% on-year to $1.4 billion, while total advances, or loans, grew 15.8% on-year in the same period, the financial house reported on Saturday.

Bank ICICI reported that it extended loans heavily to the business side of its loan portfolio in the fiscal fourth period and year, ended March 31.

While the bank's retail loan portfolio grew by 9.5% on-year in the fourth period, the ICICI business-loan portfolio grew by 24.4%

on-year, reported ICICI.

Meanwhile, total ICICI Bank deposits increased by 11.4% on-year to $189.2 billion, at the end of the fiscal fourth quarter.

The bank operation is well-capitalized, said ICICI.

The bank's total capital adequacy ratio at the end of the fourth period was 17.18% and the common equity tier 1 (CET1) ratio

was 16.35%, which was above the regulatory requirements of 11.70% and 8.20% respectively, advised ICICI.

Based on the financial results, the ICICI board recommended a dividend equivalent to $ 0.25 per ADS (American Depositary Share).

.

Established in 1955, ICICI Bank is part of the ICICI Group. It was established by the World Bank, the Government of India, and industry representatives to foster industrial development.

ICICI is one of India's largest financial houses, and is regarded as one of three domestic "systemically important banks" by the central bank Reserve Bank of India (RBI). The other two such banks are HDFC Bank (NSE:HDFCBANK, BOM:500180, HDB) and the State Bank of India (NSE:SBIN, BOM:500112).

ICICI shares on Monday closed up 0.9%.

相關文章

Asia

Dizal Pharma將在美國臨床腫瘤學會年會上發表三種藥物的研究成果。

根據週三在上海證券交易所發布的公告顯示,江蘇迪扎爾製藥(SHA:688192)表示,將在美國臨床腫瘤學會(ASCO)年會上公佈其新藥sunvozertinib片劑、golidocitinib膠囊和DZD6008的最新研究成果。 sunvozertinib和DZD6008皆用於治療非小細胞肺癌,而golidocitinib則用於治療T細胞淋巴瘤。研究結果顯示,這些藥物均取得了正面成果,尤其是DZD6008,其具有顯著的抗腫瘤活性且安全性良好。 該生技公司的股價在午盤交易中上漲不到2%。

$SHA:688192
Asia

Critica將於3月季度啟動西澳大利亞稀土計畫範圍界定研究。

根據週三提交給澳洲證券交易所的文件顯示,Critica(ASX:CRI)表示,位於西澳大利亞的Jupiter稀土計畫的初步研究已於今年3月季度正式啟動。 該研究整合了選礦、下游加工、基礎設施和開發假設,旨在確定一個基準開發路徑。 公司計劃在6月季度繼續完成Jupiter專案140個鑽孔的資源升級鑽探工作。此外,該公司還計劃準備並運送20,000公斤散裝樣品進行中試規模處理,以支援持續的最佳化、性能提升和中間精礦的生產。

$ASX:CRI
Asia

北太平洋銀行的收購要約確保了對卡里爾銀行的控制權

北太平洋銀行(東京證券交易所代號:8524)週三在東京證券交易所發佈公告稱,其對Career Bank的股份收購要約已獲成功,持股比例增至88.26%,使Career Bank成為其子公司。 北太平洋銀行此次收購了852,487股Career Bank股份,超過了完成交易所需的最低收購數量。 交易結算將於4月28日開始,屆時Career Bank將正式併入北太平洋銀行的財務報表。 北太平洋銀行計劃啟動相關程序,使Career Bank成為其全資子公司,並將其股票從札幌證券交易所下市。此次收購總成本約為15億日圓。

$TYO:8524